International Surgical Outcomes Study Group. Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth. 2016;117:601–9.

Article  Google Scholar 

Fortun J, Martin-Davila P, Pascual J, Cervera C, Moreno A, Gavalda J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis. 2010;12:397–405.

Article  CAS  PubMed  Google Scholar 

van Kooten RT, Bahadoer RR, Peeters K, Hoeksema JHL, Steyerberg EW, Hartgrink HH, et al. Preoperative risk factors for major postoperative complications after complex gastrointestinal cancer surgery: a systematic review. Eur J Surg Oncol. 2021;47:3049–58.

Article  PubMed  Google Scholar 

Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251:807–18.

Article  PubMed  Google Scholar 

Kurita N, Miyata H, Gotoh M, Shimada M, Imura S, Kimura W, et al. Risk model for distal gastrectomy when treating gastric cancer on the basis of data from 33,917 Japanese patients collected using a nationwide web-based data entry system. Ann Surg. 2015;262:295–303.

Article  PubMed  Google Scholar 

Smits FJ, Verweij ME, Daamen LA, van Werkhoven CH, Goense L, Besselink MG, et al. Impact of complications after pancreatoduodenectomy on mortality, organ failure, hospital stay, and readmission: analysis of a nationwide audit. Ann Surg. 2022;275:e222–e8.

Article  PubMed  Google Scholar 

Baiocchi GL, Giacopuzzi S, Reim D, Piessen G, Costa PMD, Reynolds JV, et al. Incidence and grading of complications after gastrectomy for cancer using the GASTRODATA registry: a European retrospective observational study. Ann Surg. 2020;272:807–13.

Article  PubMed  Google Scholar 

WHO. Guidelines for Safe Surgery 2009: Safe Surgery Saves Lives. Geneva; 2009.

Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6:86.

Article  PubMed  PubMed Central  Google Scholar 

Andersson R, Andersson B, Andersson E, Eckerwall G, Norden M, Tingstedt B. Immunomodulation in surgical practice. HPB (Oxf). 2006;8:116–23.

Article  CAS  Google Scholar 

Adiamah A, Skorepa P, Weimann A, Lobo DN. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg. 2019;270:247–56.

Article  PubMed  Google Scholar 

Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.

Article  CAS  PubMed  Google Scholar 

Hernandez R, Poder J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22:614–28.

Article  CAS  PubMed  Google Scholar 

Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–32.

Article  CAS  PubMed  Google Scholar 

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30:1902–13.

Article  CAS  PubMed  Google Scholar 

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.

PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence. NICE guidance “Conditions and diseases” United Kingdom 2025 [cited 31 January 2025]. Available from: https://www.nice.org.uk/guidance/conditions-and-diseases.

US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 2017, November 27. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 [cited 20th February 2025].

Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.cochrane.org/handbook.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article  PubMed  PubMed Central  Google Scholar 

Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol. 2011;64:1277–82.

Article  PubMed  Google Scholar 

Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.

Article  PubMed  Google Scholar 

J. Sweeting M, J. Sutton A, C. Lambert P. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–75.

Article  Google Scholar 

Angelini C, Bovo G, Muselli P, Mussi C, Crippa S, Caprotti R, et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results. Hepato Gastroenterol. 2006;53:141–4.

CAS  Google Scholar 

Brivio F, Fumagalli L, Lissoni P, Nardone A, Nespoli L, Fattori L, et al. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C. Anticancer Res. 2006;26:599–603.

CAS  PubMed  Google Scholar 

Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology. 1996;53:263–8.

Article  CAS  PubMed  Google Scholar 

Brivio F, Lissoni P, Gilardi R, Ferrante R, Vigore L, Curzi L, et al. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients. J Biol Regul Homeost Agents. 2000;14:200–3.

CAS  PubMed  Google Scholar 

Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, et al. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology. 1992;49:215–8.

Article  CAS  PubMed  Google Scholar 

Brivio F, Lissoni P, Perego MS, Lissoni A, Fumagalli L. Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications. J Biol Regul Homeost Agents. 2001;15:370–4.

CAS  PubMed  Google Scholar 

Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, et al. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol. 2007;14:1295–304.

Article  PubMed  Google Scholar 

Deehan DJ, Heys SD, Ashby J, Eremin O. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol. 1995;21:16–22.

Article  CAS  PubMed  Google Scholar 

Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents. 1995;9:31–3.

CAS  PubMed  Google Scholar 

Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res. 1992;52:5765–9.

CAS  PubMed  Google Scholar 

Romano F, Cesana G, Caprotti R, Bovo G, Uggeri F, Piacentini MG, et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepato Gastroenterol. 2006;53:634–8.

CAS  Google Scholar 

Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, et al. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol. 2004;88:240–7.

Article  CAS  PubMed  Google Scholar 

Uggeri F, Caprotti R, De Grate L, Crippa S, Nobili C, Penati C, et al. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepato Gastroenterol. 2009;56:861–5.

CAS